Spiropyrrolidine Antiviral Agents Inhibiting 3CLpro
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for coronavirus infections are inadequate, with no effective compounds approved to inhibit the 3C-Like protease (3CLpro) that is critical for the coronavirus life cycle, leading to a high unmet clinical need for more effective treatments.
Innovation Solution
Development of novel antiviral compounds represented by Formula (I) and their pharmaceutical compositions that inhibit the 3C-Like protease, interfering with the coronavirus life cycle and replication by targeting the 3CLpro, thereby preventing the polyprotein processing in host cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for coronavirus infections, then treatment options are limited, but effectiveness is inadequate with no compounds approved to inhibit 3CLpro
Solution Approach 1:
The invention segments the broad therapeutic need into specific molecular targets (3CLpro protease) and develops compounds tailored to inhibit this specific enzyme. The spiro-pyrrolidine structure is designed to specifically bind and inhibit 3CLpro, providing a targeted approach rather than broad-spectrum therapy, thereby improving reliability through mechanism-based inhibition.
Solution Approach 2:
The invention modifies chemical parameters by developing compounds with specific molecular structures (spiro-pyrrolidine core with varying substituents R1-R6) to optimize 3CLpro inhibition. By systematically varying structural parameters and testing against 3CLpro, the invention identifies compounds with improved inhibitory activity, thus enhancing therapeutic effectiveness.
2Reliability
If novel compounds are developed to inhibit 3CLpro, then therapeutic effectiveness is improved, but development complexity and time are increased
Solution Approach 1:
The invention performs preliminary action by designing compounds with a predefined spiro-pyrrolidine core structure that is already optimized for 3CLpro binding. The core structure incorporates key pharmacophore elements (amidine group, heteroaryl substituents) that pre-establish favorable interactions with the protease active site, reducing the need for extensive later optimization and simplifying the development process.
Solution Approach 2:
The spiro-pyrrolidine core structure serves multiple functions: it provides the three-dimensional geometry for optimal binding to 3CLpro, incorporates the catalytic inhibitor pharmacophore, and allows for systematic exploration of substituent effects. This multi-functional design reduces development complexity by consolidating multiple design requirements into a single versatile molecular scaffold.
Data Source
AI summary
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.